References
- Aisner J: Should we intensify combination chemotherapy for SCLC? Proc Fifth World Conference on Lung Cancer, Interlaken, August 28 – Sept. 1, 1988. Lung Cancer 1988; 4 suppl. 51.
- Smith JF. Chemotherapy for small cell lung cancer. Proc Fifth World Conference on Lung Cancer, Interlaken, August 28 – Se988. Lung Cancer 1988; 4 suppl. 49.
- Hansen HH, Rorth M. Lung cancer. In: H.M. Pineedo, D.L. Longo and B.A. Chabner, eds. Cancer chemotherapy and biological response modifiers. Annual 10. Amsterdam: Elsevier Science Publishers B.V., 1988: 222–240.
- Lelli G, Casadio M, Giordani S, Giuliotti C, Canova N, Martoni A, Pannuti F. 4’Epidoxorubicin plus cisplatin as first-line therapy in the treatment of small cell bronchogenic carcinoma. Chemioterapia, 1987; 2: 134–136.
- Broder LE, Selawry OS, Chargulu KN, Alan NG, Bag well SB. A controlled clinical trial testing two potentially non cross resistant chemotherapy regimens in small cell carcinoma of the lung. Chest 1981; 79: 327–335.
- Cohen MH, Ihde DC, Bunn PA. Cyclic alternating combination chemotherapy for smalli cell bronchogenic carcinoma. Cancer Treat Rep. 1979; 63: 163–170.
- Evans WK, Murray N, Feld R. Canadian multicenter randomized trial comparing standard and alternating combination chemotherapy in extensive small cell lung cancer. Proc Am Soc Clin Oncol 1986; 5: 169.
- Eagan RT, Carr DT, Lee RE, Frytak S, Rubin J, Coles DT. Phase II studies of polychemotherapy regimens in small cell lung cancer. Cancer Treat Rep 1977; 61: 43–95.
- Estape J, Milla A, Agusti A, Sanches-Uoret J, Santabarbara P, Rozmann C. VP 16 plus cyclophosphamide in the treatment of advanced lung cancer. Cancer 1983; 51: 385–389.
- Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47: 207–214.
- Spitzer G., Farha P, Valdivieso M, et al. High-dose intensification therapy with autologous bone marrow transplantation for limited small-cell bronchogenic carcinoma. J Clin Oncol 1986; 4:4–13.
- Ihde DC, Deisseroth AB, Lichter AS, et al. Late intensive combined modality therapy followed by autologous bone marrow infusion in extensive combined modality therapy followed by autologous bone marrow infusion in extensive stage small cell lung cancer. J Clin Oncol 1986; 4: 1443–1454.
- Blackstein M. Epirubicin in small cell lung cancer: A phase II study. Proceedings of the International Italian-Germanic Symposium on Oncology, Berlin 13–15 October 1988: 18.
- Eckhardt S. Experience with high dose epirubicin in untreated small cell lung cancer patients. Fifth European Conference on Clinical Oncology, London 3–7 Sept, 1989, Statellite Symposium «New Dimensions in Epirubicin», p. 4.